major
impact
respiratori
viru
infect
patient
hematolog
malign
hematopoiet
stem
cell
transplant
solid
organ
transplant
recogn
last
decad
immunocompromis
popul
respiratori
virus
respons
lower
respiratori
tract
infect
associ
signific
morbid
mortal
detect
viral
rna
respiratori
sampl
suggest
viral
contribut
respiratori
symptomatolog
patholog
issu
particular
import
immunocompromis
patient
may
infect
sever
agent
prone
bacteri
superinfect
addit
respiratori
virus
impact
socal
atyp
bacteria
mycoplasma
pneumonia
bordetella
pertussi
chlamydophila
pneumonia
legionella
pneumophila
fungi
pneumocysti
jirovecii
aspergillu
speci
immunocompromis
host
also
need
establish
larg
studi
primari
goal
present
studi
describ
epidemiolog
respiratori
pathogen
larg
twocentr
group
immunocompromis
patient
symptom
upper
lower
respiratori
tract
infect
use
multiparamet
custom
respiratori
array
card
target
virus
bacteria
fungi
simultan
addit
secondari
goal
investig
possibl
associ
pathogen
detect
presenc
versu
absenc
mono
versu
coinfect
key
clinic
paramet
hospitalbas
retrospect
cohort
studi
conduct
two
tertiari
care
hospit
academ
erasm
hospit
brussel
gener
stjan
hospit
brugesostend
inbetween
distanc
km
adult
immunocompromis
patient
symptom
upper
lower
respiratori
tract
infect
underw
test
respiratori
pathogen
retrospect
includ
decemb
june
period
stjan
hospit
decemb
decemb
period
patient
erasm
hospit
patient
least
one
follow
acut
respiratori
symptom
often
associ
fever
rhinorrhea
cough
sputum
dyspnea
unexplain
lung
function
declin
new
chest
xray
abnorm
patient
sampl
exclud
respiratori
symptom
start
day
first
sampl
collect
sampl
differ
respiratori
episod
includ
episod
separ
least
month
patient
free
respiratori
infecti
symptom
separ
episod
immunocompromis
statu
defin
presenc
diseas
andor
treatment
known
impair
immun
system
solid
organ
transplant
sot
immunosuppress
therapi
group
solid
group
hematolog
malign
group
chemotherapi
underli
diseas
need
longterm
highdos
corticosteroid
therapi
immunosuppress
therapi
group
patient
infect
hiv
count
also
includ
group
follow
clinic
detail
collect
retrospect
use
structur
case
report
form
age
gender
underli
diseas
influenza
vaccin
statu
admiss
unit
date
hospit
length
stay
icu
admiss
need
supplement
oxygen
therapi
andor
mechan
ventil
antivir
andor
antibacteri
treatment
surviv
inclus
collect
clinic
data
perform
one
microbiologist
hospit
patient
sampl
prospect
test
stjan
hospit
retrospect
test
erasm
hospit
custom
tac
respiratori
panel
premarket
version
cambridgebrug
respect
includ
test
pathogen
describ
previous
import
note
assay
herp
simplex
viru
yet
present
version
card
thu
includ
sampl
stjan
hospit
detail
procedur
describ
previous
data
present
entir
studi
group
stratifi
underli
condit
assess
potenti
differ
patient
characterist
regard
epidemiolog
respiratori
pathogen
key
clinic
paramet
data
analyz
use
graphpad
graphpad
softwar
inc
san
diego
ca
usa
stataic
pearson
chisquar
test
fisher
exact
test
appropri
use
compar
posit
rate
outcom
differ
popul
mannwhitneywilcoxon
test
use
compar
nongaussian
distribut
variabl
multivari
logist
regress
analysi
perform
sampl
sampl
without
influenza
infect
identifi
clinic
characterist
independ
associ
presenc
pathogen
clinic
characterist
includ
model
except
length
stay
collinear
hospit
goodnessoffit
hosmerlemeshow
test
use
verifi
model
adjust
appropri
data
result
p
consid
signific
four
hundredthirti
five
sampl
obtain
immunocompromis
patient
baselin
patient
characterist
shown
tabl
group
patient
underw
allo
autohematolog
stem
cell
transplant
hsct
receiv
transplant
less
day
respiratori
episod
therefor
inclus
total
nasopharyng
swab
univers
transport
medium
utmrt
copan
diagnost
ca
usa
bronchoalveolar
lavag
bal
sampl
includ
overal
patient
hospit
respiratori
episod
admiss
rate
intens
care
unit
among
patient
male
femal
patient
die
within
day
first
respiratori
episod
differ
signific
p
male
femal
patient
die
within
day
first
respiratori
episod
differ
signific
p
mortal
rate
within
day
first
respiratori
episod
significantli
higher
patient
older
year
old
p
nearli
one
third
patient
medic
record
contain
inform
influenza
vaccin
take
account
patient
influenza
vaccin
statu
known
vaccin
rate
differ
studi
group
amount
overal
coverag
overal
posit
rate
tac
posit
one
pathogen
one
pathogen
posit
rate
significantli
differ
nasopharyng
swab
bal
sampl
correct
multipl
comparison
posit
rate
tac
group
hematolog
disord
significantli
lower
group
p
number
sampl
posit
one
pathogen
differ
significantli
group
overal
pathogen
distribut
genu
level
follow
influenza
rhinovirus
coronavirus
p
jirovecii
rsv
cmv
frequent
encount
follow
hsv
hmpv
parainfluenza
virus
influenza
b
aspergillu
speci
adenoviru
enteroviru
bocaviru
l
pneumophila
pneumonia
b
pertussi
b
parapertussi
detect
limit
number
sampl
frequent
involv
coinfect
rhinoviru
n
influenza
viru
n
cmv
n
p
jirovecii
n
hsv
n
coronaviru
n
sampl
posit
atyp
bacteri
pathogen
well
posit
one
viral
pathogen
detail
result
shown
tabl
fig
nasopharyng
swab
significantli
higher
posit
rate
influenza
p
coronavirus
p
bronchoalveolar
lavag
sampl
frequent
posit
hsv
p
cmv
p
p
jirovecii
p
aspergillu
speci
p
median
ct
valu
rang
opportunist
pathogen
bal
sampl
ct
hsv
ct
cmv
ct
p
jirovecii
ct
aspergillu
speci
retrospect
gather
clinic
paramet
compar
patient
posit
versu
neg
tac
result
tabl
length
stay
alway
restrict
respiratori
episod
case
much
longer
due
exampl
comorbid
chemotherapi
cure
infecti
syndrom
even
long
delay
transfer
rehabilit
center
administr
antibiot
andor
antivir
often
start
empir
treatment
respiratori
infect
patient
also
prophylact
drug
patient
antivir
therapi
frequent
treat
oseltamivir
acyclovir
val
ganciclovir
ribavirin
overal
patient
respiratori
pathogen
found
significantli
like
requir
supplement
oxygen
vs
p
treat
antivir
vs
p
impact
icu
admiss
mechan
ventil
requir
antibacteri
therapi
mortal
exclud
patient
posit
result
influenza
b
virus
find
chang
tabl
show
detail
result
patient
episod
per
patient
group
group
patient
hospit
like
posit
respiratori
pathogen
p
multivari
analysi
show
adjust
presenc
predictor
model
administr
supplement
oxygen
antivir
therapi
still
statist
associ
presenc
pathogen
p
clinic
paramet
compar
patient
one
singl
pathogen
found
tac
versu
patient
posit
one
pathogen
tabl
signific
differ
group
solid
organ
transplant
hematolog
oncolog
part
main
activ
erasm
stjan
hospit
respect
studi
includ
nearli
immunocompromis
patient
present
hospit
symptom
respiratori
infect
perform
respiratori
tac
use
studi
describ
previous
overal
posit
rate
rel
high
expect
includ
symptomat
patient
influenza
viru
frequent
encount
pathogen
proport
flu
infect
immunocompromis
patient
describ
literatur
vari
due
variabl
natur
influenza
viru
abil
caus
annual
outbreak
differ
intens
influenza
epidem
studi
period
high
intens
long
durat
belgium
overal
sampl
posit
noninfluenza
virus
socal
common
cold
virus
rhinoviru
coronaviru
frequent
encount
reflect
epidemiolog
adult
popul
live
commun
line
find
describ
literatur
addit
low
preval
atyp
bacteri
pathogen
might
explain
exclus
sampl
taken
day
onset
symptom
virus
bocaviru
adenoviru
enteroviru
infrequ
adult
popul
studi
show
rel
high
incid
opportunist
pathogen
bal
sampl
hsv
posit
rate
might
underestim
sinc
target
present
tac
use
stjan
bruggeoostend
hospit
median
ct
valu
p
jirovecii
indic
signific
pathogen
load
nearli
patient
posit
result
p
jirovecii
bal
treat
highdos
cotrimoxazol
least
day
data
exist
epidemiolog
impact
opportunist
pathogen
p
jirovecii
cmv
hsv
aspergillu
speci
immunocompromis
patient
quantit
assay
work
arbitrari
cutoff
ct
valu
seem
critic
determin
clinic
relev
although
everi
posit
result
bal
sampl
could
clinic
import
especi
group
patient
ct
valu
aspergillu
speci
pneumocysti
may
point
earli
phase
reactiv
hand
may
correspond
colon
contamin
compar
two
main
patient
group
hematolog
oncolog
patient
lower
tac
posit
rate
sot
patient
less
like
coinfect
although
associ
statist
signific
observ
differ
might
explain
differ
type
level
immunosuppress
interestingli
influenza
viru
coronavirus
common
hematolog
oncolog
patient
sot
patient
rate
might
bias
due
shorter
inclus
period
stjan
hospit
cover
influenza
epidem
rsv
peak
hematolog
patient
includ
sinc
two
hospit
differ
inclus
profil
sinc
geograph
separ
might
also
bias
differ
pathogen
preval
patient
group
howev
two
center
km
climat
similar
region
patient
test
posit
respiratori
pathogen
like
treat
supplement
oxygen
antivir
therapi
clinic
impact
influenza
viru
infect
well
known
even
patient
posit
influenza
virus
exclud
analysi
presenc
respiratori
pathogen
still
associ
need
supplement
oxygen
antivir
treatment
studi
also
reveal
signific
associ
posit
respiratori
viru
pcr
presenc
acut
respiratori
diseas
studi
howev
associ
antivir
therapi
may
confound
sinc
treat
clinician
blind
result
erasm
hospit
tac
analysi
perform
retrospect
clinician
awar
convent
viral
test
result
base
direct
fluoresc
antibodi
test
viral
cultur
stjan
hospit
clinician
receiv
result
tac
analysi
within
h
sampl
limit
studi
inclus
period
month
longer
erasm
hospit
howev
sinc
winter
spring
season
cover
hospit
sampl
includ
erasm
hospit
extra
period
cultur
bacteria
potenti
causal
pathogen
respiratori
infect
taken
account
might
bias
result
clinic
impact
test
respiratori
pathogen
mono
versu
coinfect
conclus
studi
describ
epidemiolog
respiratori
virus
atyp
bacteria
fungi
larg
group
symptomat
immunocompromis
patient
analysi
provid
evid
relationship
pathogen
detect
need
supplement
oxygen
associ
differ
exclus
result
posit
influenza
virus
noninfluenza
virus
appear
contribut
sever
respiratori
diseas
patient
compromis
immun
